News | May 12, 2026
JB Chemicals reports muted Q4 FY26 as integration resets business
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Expands manufacturing push & locks in major growth deals
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The company posted revenue of Rs. 703 crore in Q4 FY26
Subscribe To Our Newsletter & Stay Updated
